Scancell Hldgs Plc (SCLP) - Net Assets
Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has net assets worth GBX-8.37 Million GBX (≈ $-1.02K USD) as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX15.38 Million ≈ $1.87K USD) and total liabilities (GBX23.75 Million ≈ $2.89K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Scancell Hldgs Plc (SCLP) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX-8.37 Million |
| % of Total Assets | -54.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | -150.14% |
| 10-Year Change | -138.38% |
| Growth Volatility | 115.16 |
Scancell Hldgs Plc - Net Assets Trend (2005–2025)
This chart illustrates how Scancell Hldgs Plc's net assets have evolved over time, based on quarterly financial data. Also explore SCLP current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Scancell Hldgs Plc (2005–2025)
The table below shows the annual net assets of Scancell Hldgs Plc from 2005 to 2025. For live valuation and market cap data, see Scancell Hldgs Plc (SCLP) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | GBX-3.83 Million ≈ $-466.61 |
-9.42% |
| 2024-04-30 | GBX-3.50 Million ≈ $-426.46 |
+43.77% |
| 2023-04-30 | GBX-6.23 Million ≈ $-758.38 |
-131.99% |
| 2022-04-30 | GBX19.48 Million ≈ $2.37K |
+154.77% |
| 2021-04-30 | GBX7.65 Million ≈ $930.54 |
-18.09% |
| 2020-04-30 | GBX9.34 Million ≈ $1.14K |
0.00% |
| 2019-04-30 | GBX9.34 Million ≈ $1.14K |
-33.03% |
| 2018-04-30 | GBX13.94 Million ≈ $1.70K |
+114.50% |
| 2017-04-30 | GBX6.50 Million ≈ $790.78 |
-34.96% |
| 2016-04-30 | GBX9.99 Million ≈ $1.22K |
+47.95% |
| 2015-04-30 | GBX6.75 Million ≈ $821.77 |
-25.59% |
| 2014-04-30 | GBX9.08 Million ≈ $1.10K |
+78.26% |
| 2013-04-30 | GBX5.09 Million ≈ $619.57 |
-26.96% |
| 2012-04-30 | GBX6.97 Million ≈ $848.21 |
+50.37% |
| 2011-04-30 | GBX4.64 Million ≈ $564.07 |
-23.35% |
| 2010-04-30 | GBX6.05 Million ≈ $735.87 |
+15.11% |
| 2009-04-30 | GBX5.25 Million ≈ $639.26 |
+401.72% |
| 2008-04-30 | GBX1.05 Million ≈ $127.41 |
-26.85% |
| 2007-04-30 | GBX1.43 Million ≈ $174.19 |
+164.63% |
| 2006-04-30 | GBX541.00K ≈ $65.82 |
-54.11% |
| 2005-08-31 | GBX1.18 Million ≈ $143.45 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Scancell Hldgs Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9141600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX1.04 Million | % |
| Other Comprehensive Income | GBX4.14 Million | % |
| Other Components | GBX82.40 Million | % |
| Total Equity | GBX-3.83 Million | 100.00% |
Scancell Hldgs Plc Competitors by Market Cap
The table below lists competitors of Scancell Hldgs Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Binakarya Jaya Abadi Tbk PT
JK:BIKA
|
$1.91 Million |
|
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
|
$1.91 Million |
|
Hedera Group publ AB
ST:HEGR
|
$1.91 Million |
|
C3is Inc.
NASDAQ:CISS
|
$1.91 Million |
|
Bastion Minerals Ltd
AU:BMO
|
$1.91 Million |
|
Melar Acquisition Corp. I Warrant
NASDAQ:MACIW
|
$1.91 Million |
|
Cathedra Bitcoin Inc
V:CBIT
|
$1.91 Million |
|
Baiya International Group Inc. Ordinary Shares
NASDAQ:BIYA
|
$1.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scancell Hldgs Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,505,000 to -3,835,000, a change of -330,000.
- Net loss of 12,272,000 reduced equity.
- New share issuances of 11,282,000 increased equity.
- Other comprehensive income increased equity by 1,358,000.
- Other factors decreased equity by 698,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-12.27 Million | -320.0% |
| Share Issuances | GBX11.28 Million | +294.19% |
| Other Comprehensive Income | GBX1.36 Million | +35.41% |
| Other Changes | GBX-698.00K | -18.2% |
| Total Change | GBX- | % |
Book Value vs Market Value Analysis
This analysis compares Scancell Hldgs Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-04-30 | GBX0.09 | GBX15.10 | x |
| 2008-04-30 | GBX0.05 | GBX15.10 | x |
| 2009-04-30 | GBX0.03 | GBX15.10 | x |
| 2010-04-30 | GBX0.05 | GBX15.10 | x |
| 2011-04-30 | GBX0.03 | GBX15.10 | x |
| 2012-04-30 | GBX0.03 | GBX15.10 | x |
| 2013-04-30 | GBX0.02 | GBX15.10 | x |
| 2014-04-30 | GBX0.04 | GBX15.10 | x |
| 2015-04-30 | GBX0.03 | GBX15.10 | x |
| 2016-04-30 | GBX0.04 | GBX15.10 | x |
| 2017-04-30 | GBX0.02 | GBX15.10 | x |
| 2018-04-30 | GBX0.04 | GBX15.10 | x |
| 2019-04-30 | GBX0.02 | GBX15.10 | x |
| 2020-04-30 | GBX0.02 | GBX15.10 | x |
| 2021-04-30 | GBX0.03 | GBX15.10 | x |
| 2022-04-30 | GBX0.02 | GBX15.10 | x |
| 2023-04-30 | GBX-0.01 | GBX15.10 | x |
| 2024-04-30 | GBX0.00 | GBX15.10 | x |
| 2025-04-30 | GBX0.00 | GBX15.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scancell Hldgs Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -260.50%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-24.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 62.20% | 40.93% | 1.33x | 1.14x | GBX747.38K |
| 2008 | -38.67% | -175324.68% | 0.00x | 1.08x | GBX-509.72K |
| 2009 | -14.96% | 0.00% | 0.00x | 1.03x | GBX-1.31 Million |
| 2010 | -28.72% | 0.00% | 0.00x | 1.07x | GBX-2.34 Million |
| 2011 | -35.57% | 0.00% | 0.00x | 1.03x | GBX-2.11 Million |
| 2012 | 7.99% | 0.00% | 0.00x | 1.04x | GBX-140.08K |
| 2013 | -37.35% | 0.00% | 0.00x | 1.06x | GBX-2.41 Million |
| 2014 | -24.49% | 0.00% | 0.00x | 1.06x | GBX-3.13 Million |
| 2015 | -35.76% | 0.00% | 0.00x | 1.09x | GBX-3.09 Million |
| 2016 | -25.85% | 0.00% | 0.00x | 1.06x | GBX-3.58 Million |
| 2017 | -54.54% | 0.00% | 0.00x | 1.08x | GBX-4.19 Million |
| 2018 | -30.09% | 0.00% | 0.00x | 1.05x | GBX-5.59 Million |
| 2019 | -60.27% | 0.00% | 0.00x | 1.13x | GBX-6.56 Million |
| 2020 | -58.97% | 0.00% | 0.00x | 1.13x | GBX-6.44 Million |
| 2021 | -79.43% | 0.00% | 0.00x | 0.45x | GBX-17.43 Million |
| 2022 | -11.40% | 0.00% | 0.00x | 2.71x | GBX-3.88 Million |
| 2023 | 0.00% | -226.45% | 0.17x | 0.00x | GBX-11.31 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-5.51 Million |
| 2025 | 0.00% | -260.50% | 0.20x | 0.00x | GBX-11.89 Million |
Industry Comparison
This section compares Scancell Hldgs Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,864,748
- Average return on equity (ROE) among peers: -251.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scancell Hldgs Plc (SCLP) | GBX-8.37 Million | 62.20% | N/A | $1.91 Million |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more